Inhibikase Therapeutics, Inc. (IKT)
NASDAQ·Healthcare·Biotechnology
$2.30
+3.85%
Mkt Cap $287.83M
Analyst Ratings
No recent rating data.
Price Target (3 analysts)
$4.00
Range $4.00 – $4.00
Implied Upside
+73.9%
Consensus $4.00 vs current $2.30
NASDAQ·Healthcare·Biotechnology
$2.30
+3.85%
Mkt Cap $287.83M
No recent rating data.
Price Target (3 analysts)
$4.00
Range $4.00 – $4.00
+73.9%
Consensus $4.00 vs current $2.30